2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Treatment Considerations, Combination Therapy, Drug Development, Therapy Sequence, Biological Therapies, Monoclonal Antibody Therapy, Non-Biological Therapies, Chemotherapy, Pharmacology, Adverse Events, Biological Processes, Molecular Biology, Clinical Practice (Health Services and Quality), Clinical Guidelines, Diseases, Lymphoid Malignancies, Myeloid Malignancies, Acute Myeloid Malignancies, Measurable Residual Disease, Research, AML, Clinical Research, Clinical Trials, Real-World Evidence, Study Population, Human, Adult, Elderly, Young Adult
PAPER

3404 Preliminary results of a Phase 2 study evaluating optimal sequencing in newly diagnosed, IDH-mutated acute myeloid leukemia (I-DATA study)

Jayanshu Jain, MD, Qiuhong Zhao, MS2, Lacey Williams, MD3, Kaitlyn M Dvorak-Kornaus, PhD4, Mary K Long, CNP5, Jill Buss, PhD6, Andrea Laganson, BS7, Ethan Hamp8, Gregory Behbehani, MD, PhD9, Kristin Koenig, MD10, Shivani Handa, MD11, James Stewart Blachly, MD12, Meixiao Long, MD13, Uma Borate, MBBS, MSc14, Mathew G. Angelos, MD, PhD15, Yazan F. Madanat, MD16, Joshua F. Zeidner, MD17, Elaine Mardis, PhD18, Ann-Kathrin Eisfeld, MD19, Alice Scott Mims, MD20
1 The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
2 The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
3 University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina, United States
4 The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
5 The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
6 The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
7 The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
8 The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
9 The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
10 Cleveland Clinic, Lorain, Ohio, United States, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
11 The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
12 The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
13 The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
14 The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
15 University of Colorado Anschutz Cancer Center, Aurora, Colorado, United States
16 University of Texas Southwestern Medical Center, Dallas, Texas, United States
17 University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina, United States
18 Nationwide Children's Hospital, Columbus, Ohio, United States
19 The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
20 The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States

Introduction: Outcomes are poor in older adults with AML (>60 years) due in part to higher rates of toxicity and inferior clinical outcomes with intensive chemotherapy. Mutations in IDH1 or IDH2 are present in 10-15% of cases of AML and are targetable. Results from the VIALE-A study revealed that venetoclax/azacitidine (ven/aza) improves overall survival (OS) compared with aza alone with particular benefit noted in the IDH-mutated subset. In contrast, the AGILE trial found ivosidenib/azacitidine (ivo/aza) led to improved OS compared with aza alone with median OS approaching 30 months.  Phase 1b/2 studies have also shown encouraging responses with enasidenib/azacitidine in IDH2-mutated AML. However, there are no head-to-head comparative data to inform the optimal frontline regimen.

Methods: I-DATA is a randomized, open-label, multicenter phase 2 trial evaluating sequencing of IDH inhibitors/azacitidine (IDHi/aza) and ven/aza in pts with IDH1- or IDH2-mutated AML with a primary endpoint of treatment failure at 24 months over the sequence of two lines of therapy (NCT05401097). Eligible pts included adults with newly diagnosed IDH1/2-mutated AML who are ineligible/unwilling to receive intensive induction with an ECOG performance score ≤2 and adequate organ function. Pts were randomized 1:1 to Arm A or Arm B. Arm A consists of treatment with IDHi/aza, followed by ven/aza on treatment failure. Arm B consists of treatment with ven/aza, followed by IDHi/aza on treatment failure. Pts were evaluable for response if they had disease assessment after starting therapy.

Results: 21 pts have been enrolled, with 10 randomized to Arm A and 11 to Arm B. 11 pts were male, with median age 72 (range, 51-89). 9 pts with IDH1 mutations were enrolled (A: n=4, B: n=5), while 12 with IDH2 were enrolled (A: n=6, B: n=6). 11 pts had normal karyotype (A: n=5, B: n=6). 2 pts had a complex karyotype, both treated on Arm B.

On Arm A (n=10), 7 pts were evaluable for response with overall response rate (ORR) of 71% (complete remission (CR): n=3; CR with incomplete recovery (CRi): n=1; CR with partial hematologic recovery (CRh): n=1). The 3 non-evaluable pts comprised 1 death from pneumonia, 1 who continued care locally and did not return for disease assessment, and 1 in ongoing follow-up. 1 pt in CR received second-line ven/aza due to intolerance (grade 3 anorexia) and maintained CR.

On Arm B (n=11), 1 withdrew prior to treatment start to receive local therapy. Of 10 patients treated on protocol, 6 were evaluable for response with an ORR of 83% (CR: n=1; CRi: n=1, CRh: n=2, morphologic leukemia-free state: n=1). The 4 non-evaluable pts comprised 1 death, 2 who pursued local follow-up, and 1 with ongoing follow-up. 3 pts went on to second-line IDHi/aza: 1 for toxicity (cytopenias), 1 with relapse who then had stable disease (SD), and 1 with SD who then achieved PR.

Of the 21 pts enrolled, 4 received allogeneic stem cell transplant (A: n=1, B: n=3). At a median follow-up of 8.1 months (range, 0.2 – 42.3) from study enrollment, 13 are deceased (6 on Arm A, 7 on Arm B) with 2 in known remission at death. Causes of death included suspected/confirmed infection (A: n=2 with 1 pt in CR, B: n=3), relapse (A: n=1, B: n=2), differentiation syndrome (A: n=1), cardiac arrest (A: n=1), respiratory failure (B: n=1), and unknown (A: n=1, B: n=1 with pt in CRh). 30- and 60-day mortality from cycle 1 day 1 were 14.3% (3/21, A: n=1, B: n=2) and 28.6% (6/21, A: n=3, B: n=3) respectively.

Conclusions: I-DATA was initially designed with a primary endpoint of treatment failure at 24 months between the two arms to evaluate sequencing of IDHi/aza and ven/aza. However, higher than anticipated mortality and patient withdrawal have limited evaluation of second-line treatment, with only 4 of 21 pts moving onto second line therapy to date. While initial response rates appear comparable to published literature, high toxicity rates limit treatment in frail AML pts. Partially decentralized trial designs should be considered to decrease the logistical burden of treatment as this contributed to withdrawal from trial. Due to the unlikely ability to answer the initial primary endpoint, the study design is being modified to compare CR/CRi rates between IDHi/aza vs ven/aza, rather than evaluating sequential treatment. Given the apparent low number of patients that move on to second line treatment, it is imperative to understand the optimal frontline regimen in IDH1/2-mutated AML patients.

Jayanshu Jain, MD: Geron - Consultancy (Includes expert testimony); Syndax - Consultancy (Includes expert testimony); AbbVie - Consultancy (Includes expert testimony)